Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Average Recommendation of “Buy” from Analysts

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. Six equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokers that have covered the stock in the last year is $41.1667.

A number of equities analysts have issued reports on KNSA shares. Wells Fargo & Company raised their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 9th. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 7th. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Finally, Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, COO Eben Tessari sold 138,614 shares of the company’s stock in a transaction dated Tuesday, August 5th. The shares were sold at an average price of $33.20, for a total transaction of $4,601,984.80. Following the completion of the transaction, the chief operating officer owned 49,915 shares of the company’s stock, valued at $1,657,178. This represents a 73.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 18,889 shares of the company’s stock in a transaction dated Monday, August 4th. The shares were sold at an average price of $32.89, for a total transaction of $621,259.21. Following the transaction, the chief financial officer directly owned 27,009 shares of the company’s stock, valued at approximately $888,326.01. This represents a 41.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 561,371 shares of company stock worth $18,825,009. Corporate insiders own 53.48% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

Hedge funds and other institutional investors have recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Kiniksa Pharmaceuticals International in the 1st quarter valued at about $301,000. GAMMA Investing LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 84.8% in the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after buying an additional 568 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Kiniksa Pharmaceuticals International by 177.1% in the first quarter. Deutsche Bank AG now owns 394,522 shares of the company’s stock valued at $8,762,000 after buying an additional 252,125 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $1,184,000. Finally, Nuveen Asset Management LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 7.3% in the fourth quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company’s stock valued at $15,737,000 after buying an additional 54,361 shares in the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Trading Down 1.4%

Shares of KNSA opened at $35.42 on Monday. The stock has a market cap of $2.62 billion, a P/E ratio of 885.72 and a beta of 0.20. The company has a 50-day moving average of $32.62 and a two-hundred day moving average of $27.61. Kiniksa Pharmaceuticals International has a 12-month low of $17.82 and a 12-month high of $37.34.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.05. The company had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.